Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 23Capecitabine 17Cisplatin 11Oxaliplatin 10Fluorouracil 9Leucovorin 8Irinotecan 7Erlotinib Hydrochloride 6pembrolizumab 5Radiotherapy 5Sorafenib 4Interleukin-12 Subunit p35 3Cholangiopancreatography, Endoscopic Retrograde 3Carboplatin 3regorafenib 2dehydroftorafur 2Watchful Waiting 2Trastuzumab 2Pancreaticoduodenectomy 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Long-Term Synaptic Depression 2Lapatinib 2Filgrastim 2Epirubicin 2Drug Therapy 2Dihematoporphyrin Ether 2Chemotherapy, Adjuvant 2Bevacizumab 2trifluridine tipiracil drug combination 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bile Duct Neoplasms × Dihydrouracil Dehydrogenase (NADP) × Clear all
NCT05266300 2022-11-01

Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.

University of Southern Denmark

Completed
722 enrolled
BreastGastrointestinal

Bile Duct Neoplasms, Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡